Abstract Library

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,

#2991 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasia G3 (NEN G3) According to 2019 WHO Classification: A Comprehensive Clinicopathological Characterization Including Mismatch Repair (MMR) Proteins, PDL1 Expression and KRAS/BRAF Status

Introduction: In the 2019 WHO FOR NEN’S classification NETG3 have been distinguished from poorly differentiated neuroendocrine carcinoma (NEC). They are heterogeneous group concerning prognosis and treatment benefit.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Ruiz G, Graselli J, Golubicki M, Rizzol M,

Keywords: G3 NEN, PD-L1, KRAS, BIOMARKERS,

#2865 Can the Efficacy of Etoposide-Platinum Chemotherapy Be Predicted by p53/pRb Status in Grade 3 Neuroendocrine Neoplasms (G3 NEN)?

Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,

Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,

#2842 Transformation to High Grade 3 (G3) Neuroendocrine Neoplasia (NEN) – Molecular Imaging, Pathologic Features and Patient Outcomes

Introduction: Transformation of lower grade to Grade 3 (G3) NEN potentially impacts prognosis & treatment options.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kong G, Callahan J, Prall O, Michael M, Hicks R,

Keywords: Transformation, G3 NEN, PET imaging, mutation, PRRT, prognosis,

#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Capodanno Y

Authors: Capodanno Y, Chen Y, Hiraoka N, Yokoyama A, Schrader J,

Keywords: MEN1, p53, Notch pathway, biomarkers, carcinogenesis, PNET,